SM04755, a Small-molecule Inhibitor of the Wnt Pathway, As a Potential Topical Treatment for Tendinopathy

Overview

Journal J Orthop Res

Publisher Wiley

Specialty Orthopedics

Date 2020 Oct 26

PMID 33104243

Citations 13

Authors

Vishal Deshmukh

Tim Seo

Alyssa L OGreen

Maureen Ibanez

Brian Hofilena

Sunil Kc

Joshua Stewart

Luis Dellamary

Kevin Chiu

Abdullah Ghias

Charlene Barroga

Sarah Kennedy

Jeyanesh Tambiah

John Hood

Yusuf Yazici

Affiliations

Soon will be listed here.

Abstract

The Wnt pathway is upregulated in tendinopathy, affecting inflammation and tenocyte differentiation. Given its potential role in tendinopathy, this signaling pathway may be a relevant target for treatment. The current study examined the therapeutic potential of SM04755, a topical, small-molecule Wnt pathway inhibitor, for the treatment of tendinopathy using in vitro assays and animal models. In vitro, SM04755 decreased Wnt pathway activity, induced tenocyte differentiation, and inhibited catabolic enzymes and pro-inflammatory cytokines in human mesenchymal stem cells, rat tendon-derived stem cells, and human peripheral blood mononuclear cells. Evaluation of the mechanism of action of SM04755 by biochemical profiling and computational modeling identified CDC-like kinase 2 (CLK2) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as molecular targets. CLK and DYRK1A inhibition by siRNA knockdown or pharmacological inhibition induced tenocyte differentiation and reduced tenocyte catabolism. In vivo, topically applied SM04755 showed therapeutically relevant exposure in tendons with low systemic exposure and no detectable toxicity in rats. Moreover, SM04755 showed reduced tendon inflammation and evidence of tendon regeneration, decreased pain, and improved weight-bearing function in rat collagenase-induced tendinopathy models compared with vehicle control. Together, these data demonstrate that CLK2 and DYRK1A inhibition by SM04755 resulted in Wnt pathway inhibition, enhanced tenocyte differentiation and protection, and reduced inflammation. SM04755 has the potential to benefit symptoms and modify disease processes in tendinopathy.

Citing Articles

Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?.

de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065798 PMC: 11279613. DOI: 10.3390/ph17070949.

The current status of various preclinical therapeutic approaches for tendon repair.

Liang W, Zhou C, Deng Y, Fu L, Zhao J, Long H Ann Med. 2024; 56(1):2337871.

PMID: 38738394 PMC: 11095292. DOI: 10.1080/07853890.2024.2337871.

In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer.

Huang C, Hsu C, Chao M, Hsu K, Lin T, Yen S Protein Sci. 2024; 33(6):e5004.

PMID: 38723164 PMC: 11081522. DOI: 10.1002/pro.5004.

Pentamidine-loaded gelatin decreases adhesion formation of flexor tendon.

Shi G, Koichi N, Wan R, Wang Y, Reisdorf R, Wilson A J Orthop Translat. 2024; 45:75-87.

PMID: 38511123 PMC: 10950576. DOI: 10.1016/j.jot.2023.10.007.

2-Desaza-annomontine (C81) impedes angiogenesis through reduced VEGFR2 expression derived from inhibition of CDC2-like kinases.

Zech T, Wolf A, Hector M, Bischoff-Kont I, Krishnathas G, Kuntschar S Angiogenesis. 2024; 27(2):245-272.

PMID: 38403816 PMC: 11021337. DOI: 10.1007/s10456-024-09906-y.

References

Monteiro M, Ramm S, Chandrasekaran V, Boswell S, Weber E, Lidberg K . A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation. J Am Soc Nephrol. 2018; 29(12):2820-2833. PMC: 6287872. DOI: 10.1681/ASN.2018040392. View

Clevers H, Loh K, Nusse R . Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014; 346(6205):1248012. DOI: 10.1126/science.1248012. View

Kahn M . Can we safely target the WNT pathway?. Nat Rev Drug Discov. 2014; 13(7):513-32. PMC: 4426976. DOI: 10.1038/nrd4233. View

Duncan P, Stojdl D, Marius R, Scheit K, Bell J . The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing. Exp Cell Res. 1998; 241(2):300-8. DOI: 10.1006/excr.1998.4083. View

Kim S, Oh H, Chang J, Kim S . Recovery of Tendon Characteristics by Inhibition of Aberrant Differentiation of Tendon-Derived Stem Cells from Degenerative Tendinopathy. Int J Mol Sci. 2020; 21(8). PMC: 7215446. DOI: 10.3390/ijms21082687. View

Coombs T, Tanega C, Shen M, Wang J, Auld D, Gerritz S . Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013; 23(12):3654-61. PMC: 3664191. DOI: 10.1016/j.bmcl.2013.02.096. View

Lee J, Zhou Z, Taub P, Ramcharan M, Li Y, Akinbiyi T . BMP-12 treatment of adult mesenchymal stem cells in vitro augments tendon-like tissue formation and defect repair in vivo. PLoS One. 2011; 6(3):e17531. PMC: 3055887. DOI: 10.1371/journal.pone.0017531. View

Fu S, Chan B, Wang W, Pau H, Chan K, Rolf C . Increased expression of matrix metalloproteinase 1 (MMP1) in 11 patients with patellar tendinosis. Acta Orthop Scand. 2003; 73(6):658-62. DOI: 10.1080/000164702321039624. View

de la Torre R, de Sola S, Pons M, Duchon A, Martinez de Lagran M, Farre M . Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res. 2013; 58(2):278-88. DOI: 10.1002/mnfr.201300325. View

10.

Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L . A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2017; 26(1):18-27. DOI: 10.1016/j.joca.2017.08.015. View

11.

Jarvinen T, Kannus P, Maffulli N, Khan K . Achilles tendon disorders: etiology and epidemiology. Foot Ankle Clin. 2005; 10(2):255-66. DOI: 10.1016/j.fcl.2005.01.013. View

12.

Yang J, Zhao Q, Wang K, Liu H, Ma C, Huang H . Isolation and biological characterization of tendon-derived stem cells from fetal bovine. In Vitro Cell Dev Biol Anim. 2016; 52(8):846-56. PMC: 5023758. DOI: 10.1007/s11626-016-0043-z. View

13.

Schon L, Gill N, Thorpe M, Davis J, Nadaud J, Kim J . Efficacy of a mesenchymal stem cell loaded surgical mesh for tendon repair in rats. J Transl Med. 2014; 12:110. PMC: 4020316. DOI: 10.1186/1479-5876-12-110. View

14.

Sineva G, Pospelov V . Inhibition of GSK3beta enhances both adhesive and signalling activities of beta-catenin in mouse embryonic stem cells. Biol Cell. 2010; 102(10):549-60. DOI: 10.1042/BC20100016. View

15.

Miller L, Parrish W, Roides B, Bhattacharyya S . Efficacy of platelet-rich plasma injections for symptomatic tendinopathy: systematic review and meta-analysis of randomised injection-controlled trials. BMJ Open Sport Exerc Med. 2017; 3(1):e000237. PMC: 5687544. DOI: 10.1136/bmjsem-2017-000237. View

16.

Riggs J, Nagy M, Elsner J, Erdman P, Cashion D, Robinson D . The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 2017; 60(21):8989-9002. DOI: 10.1021/acs.jmedchem.7b01223. View

17.

Liu S, Yang R, Lane J . Collagen in tendon, ligament, and bone healing. A current review. Clin Orthop Relat Res. 1995; (318):265-78. View

18.

John T, Lodka D, Kohl B, Ertel W, Jammrath J, Conrad C . Effect of pro-inflammatory and immunoregulatory cytokines on human tenocytes. J Orthop Res. 2010; 28(8):1071-7. DOI: 10.1002/jor.21079. View

19.

Chen X, Yin Z, Chen J, Shen W, Liu H, Tang Q . Force and scleraxis synergistically promote the commitment of human ES cells derived MSCs to tenocytes. Sci Rep. 2012; 2:977. PMC: 3522101. DOI: 10.1038/srep00977. View

20.

Tsuzaki M, Guyton G, Garrett W, Archambault J, Herzog W, Almekinders L . IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. J Orthop Res. 2003; 21(2):256-64. DOI: 10.1016/S0736-0266(02)00141-9. View